To this end, using the parental mouse colon carcinoma cell line CT26 (CT26-WT) and its EMMPRIN knocked-down counterpart (CT26-KD), we demonstrate that reduced EMMPRIN expression changed spheroid morphology, inhibited proliferation and angiogenesis, and enhanced drug resistance, invasiveness, the EMT status, and dormancy. The gene discussed is DDX53; the disease is colon carcinoma.